Skip to Content

New Drug Approvals Archive - March 2008

March 2008

Fusilev (levoleucovorin) for Injection - formerly Isovorin

Date of Approval: March 7, 2008
Company: Spectrum Pharmaceuticals, Inc.
Treatment for: Methotrexate Rescue, Folic Acid Antagonist Overdose, Colorectal Cancer

Fusilev (levoleucovorin calcium) is a folate analog indicated for rescue after high-dose methotrexate therapy in osteosarcoma, diminishing the toxicity and counteracting the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists, and for use in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer.

Read more: Fusilev (levoleucovorin) FDA Approval History

Artiss (fibrin sealant (human)) Topical Solution

Date of Approval: March 19, 2008
Company: Baxter Healthcare Corporation
Treatment for: Burns - External

Artiss (fibrin sealant (human)) is a slow-setting fibrin sealant indicated for use in adhering skin grafts in adult and pediatric burn patients and for tissue adherence in facial rhytidectomy (face-lift) surgery.

Read more: Artiss (fibrin sealant (human)) FDA Approval History

Treanda (bendamustine hydrochloride) Injection

Date of Approval: March 20, 2008
Company: Cephalon, Inc.
Treatment for: Chronic Lymphocytic Leukemia, non-Hodgkin's Lymphoma

Treanda (bendamustine) is a purine alkylator hybrid chemotherapy agent indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) and relapsed indolent non-Hodgkin's lymphoma.

Read more: Treanda (bendamustine hydrochloride) FDA Approval History

New Drug Approvals Archive